Hitoshi Ishikawa1, Hiroyuki Katoh2, Takuya Kaminuma2, Hidemasa Kawamura2, Kazuto Ito3, Hiroshi Matsui3, Junko Hirato4, Nobuaki Shimizu5, Yutaka Takezawa6, Hiroshi Tsuji7, Kazuhiro Suzuki2, Tatsuya Ohno2, Takashi Nakano2. 1. Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan hishikawa@pmrc.tsukuba.ac.jp. 2. Heavy Ion Medical Research Center, Gunma University, Gunma, Japan. 3. Department of Urology, Gunma University Graduate School of Medicine, Gunma, Japan. 4. Department of Pathology, Gunma University Graduate School of Medicine, Gunma, Japan. 5. Department of Urology, Gunma Cancer Center, Gunma, Japan. 6. Department of Urology, Isesaki Municipal Hospital, Isesaki, Gunma, Japan. 7. Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
Abstract
AIM: To prospectively evaluate the feasibility of carbon-ion radiotherapy (C-ion RT) for prostate cancer using a new compact-sized accelerator. PATIENTS AND METHODS: Seventy-six patients underwent C-ion RT at our center using a recommended dose fractionation of 57.6 GyE in 16 fractions established at the National Institute of Radiological Sciences. Health-related Quality of Life (HRQOL) assessment was also performed using the Medical Outcome Study 8-items Short Form Health Survey (SF-8) questionnaire. RESULTS: The median follow-up time was 51 months (range=8-58 months). Grade 2 gastrointestinal and genitourinary complications developed in 1 (1.3%) and 5 (6.6%) patients, respectively. Recurrences occurred in 4 patients, and the 4-year biochemical relapse-free rate was 94.6%. The HRQOL scores after C-ion RT were objectively well-maintained. CONCLUSION: Irrespective of the small number of patients of the study, C-ion RT for prostate cancer using the first commercial-based accelerator reproduced the toxicity outcomes at the NIRS. Copyright
AIM: To prospectively evaluate the feasibility of carbon-ion radiotherapy (C-ion RT) for prostate cancer using a new compact-sized accelerator. PATIENTS AND METHODS: Seventy-six patients underwent C-ion RT at our center using a recommended dose fractionation of 57.6 GyE in 16 fractions established at the National Institute of Radiological Sciences. Health-related Quality of Life (HRQOL) assessment was also performed using the Medical Outcome Study 8-items Short Form Health Survey (SF-8) questionnaire. RESULTS: The median follow-up time was 51 months (range=8-58 months). Grade 2 gastrointestinal and genitourinary complications developed in 1 (1.3%) and 5 (6.6%) patients, respectively. Recurrences occurred in 4 patients, and the 4-year biochemical relapse-free rate was 94.6%. The HRQOL scores after C-ion RT were objectively well-maintained. CONCLUSION: Irrespective of the small number of patients of the study, C-ion RT for prostate cancer using the first commercial-based accelerator reproduced the toxicity outcomes at the NIRS. Copyright